Literature DB >> 17239467

Comparison of gene expression efficiency and innate immune response induced by Ad vector and lipoplex.

Haruna Sakurai1, Fuminori Sakurai, Kenji Kawabata, Tomomi Sasaki, Naoya Koizumi, Haiying Huang, Katsuhisa Tashiro, Shinnosuke Kurachi, Shinsaku Nakagawa, Hiroyuki Mizuguchi.   

Abstract

Vectors for gene expression are the essential tools for both gene therapy and basic research. There are two groups of gene therapy vectors, viral and non-viral vectors. At present, toxicity triggered by vectors is one of the major concerns for clinical trials. In general, non-viral vectors, such as plasmid DNA-cationic liposome complex (lipoplex), are thought to be safer than viral vectors, such as adenovirus (Ad) vector, although lipoplex is less efficient in term of gene expression than the Ad vector. However, there has been no study directly comparing the gene expression efficiency and safety of viral and non-viral vectors. Here, we present evidence that the Ad vector shows much more efficient gene expression and is safer than lipoplex, at least with respect to the innate immune response. After being systemically administered to mice, the Ad vector showed a transduction efficiency that was 2 to 5 log orders higher than that of lipoplex, depending on the organ. On the other hand, surprisingly, the administration of lipoplex produced a greater amount of inflammatory cytokines such as interleukin-6, interleukin-12, and tumor necrosis factor-alpha than did the administration of the Ad vector, whereas a comparable level of hepatotoxicity was induced by these vectors. The production of inflammatory cytokines induced by the injection of lipoplex was reduced when the CpG motifs were removed completely from plasmid DNA. Thus, care should be taken to ensure the innate immune response induced by gene therapy vectors, especially lipoplex.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17239467     DOI: 10.1016/j.jconrel.2006.11.030

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  9 in total

Review 1.  Tissue engineering tools for modulation of the immune response.

Authors:  Ryan M Boehler; John G Graham; Lonnie D Shea
Journal:  Biotechniques       Date:  2011-10       Impact factor: 1.993

Review 2.  Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics.

Authors:  Long Xu; Thomas Anchordoquy
Journal:  J Pharm Sci       Date:  2011-01       Impact factor: 3.534

3.  TLR9 and IRF3 cooperate to induce a systemic inflammatory response in mice injected with liposome:DNA.

Authors:  Wendy E Walker; Carmen J Booth; Daniel R Goldstein
Journal:  Mol Ther       Date:  2010-02-09       Impact factor: 11.454

4.  A DNA microarray-based analysis of the host response to a nonviral gene carrier: a strategy for improving the immune response.

Authors:  Hiroto Hatakeyama; Erika Ito; Momoko Yamamoto; Hidetaka Akita; Yasuhiro Hayashi; Kazuaki Kajimoto; Noritada Kaji; Yoshinobu Baba; Hideyoshi Harashima
Journal:  Mol Ther       Date:  2011-03-08       Impact factor: 11.454

Review 5.  Lipid-based systemic delivery of siRNA.

Authors:  Yu-Cheng Tseng; Subho Mozumdar; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2009-03-26       Impact factor: 15.470

6.  Reducing neuroinflammation by delivery of IL-10 encoding lentivirus from multiple-channel bridges.

Authors:  Daniel J Margul; Jonghyuck Park; Ryan M Boehler; Dominique R Smith; Mitchell A Johnson; Dylan A McCreedy; Ting He; Aishani Ataliwala; Todor V Kukushliev; Jesse Liang; Alireza Sohrabi; Ashley G Goodman; Christopher M Walthers; Lonnie D Shea; Stephanie K Seidlits
Journal:  Bioeng Transl Med       Date:  2016-07-19

Review 7.  Rationale and Application of PEGylated Lipid-Based System for Advanced Target Delivery of siRNA.

Authors:  Xuemei Ge; Lijuan Chen; Bo Zhao; Weien Yuan
Journal:  Front Pharmacol       Date:  2021-01-20       Impact factor: 5.810

8.  Evaluation of biodistribution and safety of adenovirus vector containing MDR1 in mice.

Authors:  ZhenZhen Zhao; Wei Liu; Yuxi Su; Jin Zhu; GaiHuan Zheng; Qing Luo; XianQing Jin
Journal:  J Exp Clin Cancer Res       Date:  2010-01-04

9.  The liver as a target organ for gene therapy: state of the art, challenges, and future perspectives.

Authors:  Frank Jacobs; Stephanie C Gordts; Ilayaraja Muthuramu; Bart De Geest
Journal:  Pharmaceuticals (Basel)       Date:  2012-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.